OPEN REGISTRY: Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults With Cancer
Pediatric and young adult cancer patients receiving immunosuppressive therapy or who have completed therapy within 12 months and plan to receive one of the FDA-approved or EUA-approved COVID-19 vaccines will be enrolled in this prospective cohort study to assess humoral and cellular immune responses to the vaccine.
This protocol provides for the collection of demographic, therapeutic and other clinical data at the time of enrollment and vaccine administration. Serial biospecimens will be collected to assess cellular and humoral immune responses and the duration of such responses at several time points. We will determine the incidence of breakthrough SARS-CoV-2 infections after vaccination and assess the durability of protection from the vaccines.
MORE INFO: ClinicalTrials.gov
